Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V; Children’s Tumor Foundation Synodos for NF2 Consortium. Angus SP, et al. Among authors: gilbert tsk. Neuro Oncol. 2018 Aug 2;20(9):1185-1196. doi: 10.1093/neuonc/noy046. Neuro Oncol. 2018. PMID: 29982664 Free PMC article.
Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth.
Krulikas LJ, McDonald IM, Lee B, Okumu DO, East MP, Gilbert TSK, Herring LE, Golitz BT, Wells CI, Axtman AD, Zuercher WJ, Willson TM, Kireev D, Yeh JJ, Johnson GL, Baines AT, Graves LM. Krulikas LJ, et al. Among authors: gilbert tsk. SLAS Discov. 2018 Sep;23(8):850-861. doi: 10.1177/2472555218773045. Epub 2018 May 9. SLAS Discov. 2018. PMID: 29742358 Free PMC article.
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, Thomas C, Burns SS, Gilbert TSK, Jiang L, Li X, Lu Q, Yuan J, He Y, Dixon SAH, Masters A, Jones DR, Yates CW, Haggarty SJ, La Rosa S, Welling DB, Stemmer-Rachamimov AO, Plotkin SR, Gusella JF, Guinney J, Morrison H, Ramesh V, Fernandez-Valle C, Johnson GL, Blakeley JO, Clapp DW; Synodos for NF2 Consortium. Chang LS, et al. Among authors: gilbert tsk. PLoS One. 2021 Jul 15;16(7):e0252048. doi: 10.1371/journal.pone.0252048. eCollection 2021. PLoS One. 2021. PMID: 34264955 Free PMC article.
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.
Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, Pecot CV, Rashid N, Houghton PJ, Wennerberg K, Cox AD, Der CJ. Vaseva AV, et al. Among authors: gilbert tsk. Cancer Cell. 2018 Nov 12;34(5):807-822.e7. doi: 10.1016/j.ccell.2018.10.001. Cancer Cell. 2018. PMID: 30423298 Free PMC article.
Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
Graves PR, Aponte-Collazo LJ, Fennell EMJ, Graves AC, Hale AE, Dicheva N, Herring LE, Gilbert TSK, East MP, McDonald IM, Lockett MR, Ashamalla H, Moorman NJ, Karanewsky DS, Iwanowicz EJ, Holmuhamedov E, Graves LM. Graves PR, et al. Among authors: gilbert tsk. ACS Chem Biol. 2019 May 17;14(5):1020-1029. doi: 10.1021/acschembio.9b00222. Epub 2019 May 1. ACS Chem Biol. 2019. PMID: 31021596 Free PMC article.
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
Blake DR, Vaseva AV, Hodge RG, Kline MP, Gilbert TSK, Tyagi V, Huang D, Whiten GC, Larson JE, Wang X, Pearce KH, Herring LE, Graves LM, Frye SV, Emanuele MJ, Cox AD, Der CJ. Blake DR, et al. Among authors: gilbert tsk. Sci Signal. 2019 Jul 16;12(590):eaav7259. doi: 10.1126/scisignal.aav7259. Sci Signal. 2019. PMID: 31311847 Free PMC article.
Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology.
Da C, Zhang D, Stashko M, Vasileiadi E, Parker RE, Minson KA, Huey MG, Huelse JM, Hunter D, Gilbert TSK, Norris-Drouin J, Miley M, Herring LE, Graves LM, DeRyckere D, Earp HS, Graham DK, Frye SV, Wang X, Kireev D. Da C, et al. Among authors: gilbert tsk. J Am Chem Soc. 2019 Oct 2;141(39):15700-15709. doi: 10.1021/jacs.9b08660. Epub 2019 Sep 20. J Am Chem Soc. 2019. PMID: 31497954 Free PMC article.
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.
Waters AM, Khatib TO, Papke B, Goodwin CM, Hobbs GA, Diehl JN, Yang R, Edwards AC, Walsh KH, Sulahian R, McFarland JM, Kapner KS, Gilbert TSK, Stalnecker CA, Javaid S, Barkovskaya A, Grover KR, Hibshman PS, Blake DR, Schaefer A, Nowak KM, Klomp JE, Hayes TK, Kassner M, Tang N, Tanaseichuk O, Chen K, Zhou Y, Kalkat M, Herring LE, Graves LM, Penn LZ, Yin HH, Aguirre AJ, Hahn WC, Cox AD, Der CJ. Waters AM, et al. Among authors: gilbert tsk. Cell Rep. 2021 Jun 29;35(13):109291. doi: 10.1016/j.celrep.2021.109291. Cell Rep. 2021. PMID: 34192548 Free PMC article.
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.
Diehl JN, Klomp JE, Snare KR, Hibshman PS, Blake DR, Kaiser ZD, Gilbert TSK, Baldelli E, Pierobon M, Papke B, Yang R, Hodge RG, Rashid NU, Petricoin EF 3rd, Herring LE, Graves LM, Cox AD, Der CJ. Diehl JN, et al. Among authors: gilbert tsk. J Biol Chem. 2021 Nov;297(5):101335. doi: 10.1016/j.jbc.2021.101335. Epub 2021 Oct 22. J Biol Chem. 2021. PMID: 34688654 Free PMC article.
21 results